RXRXRECURSION PHARMACEUTICALS, ...

Nasdaq recursion.com


$ 8.79 $ 0.32 (3.78 %)    

Thursday, 02-May-2024 15:59:59 EDT
QQQ $ 427.55 $ 2.31 (0.54 %)
DIA $ 382.31 $ 0.79 (0.21 %)
SPY $ 504.99 $ 0.59 (0.12 %)
TLT $ 88.87 $ 0.65 (0.74 %)
GLD $ 213.12 $ 0.66 (0.31 %)
$ 8.34
$ 8.47
$ 0.00 x 0
$ 0.00 x 0
$ 8.31 - $ 8.79
$ 4.54 - $ 16.75
5,750,340
na
1.73B
$ 2.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 02-27-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-23-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner

Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and C...

 cathie-woods-ark-invest-sells-20m-coinbase-shares-as-bitcoin-trades-over-70k-buys-palantir-sells-nvidia-stock

On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technolog...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

 nvidias-ai-revolution-is-transforming-healthcare-with-johnson--johnson-and-ge-healthcare-partnerships

Nvidia announces partnerships with J&J and GE Healthcare to integrate generative AI into surgery and medical imaging at GTC...

 why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

 nvidias-secret-weapon-is-not-just-chips-but-investing-15b-in-ais-rising-stars-report-unveils-ceo-jensen-huangs-10-year-vision

Additionally, the investments help Nvidia "build out the future ecosystem of businesses that depend on its technology" ...

 keybanc-maintains-overweight-on-recursion-pharmaceuticals-raises-price-target-to-16

Keybanc analyst Scott Schoenhaus maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and raises the price ta...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

 recursion-pharmaceuticals-stock-is-sliding-wednesday-whats-going-on

Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinica...

 why-beyond-meat-shares-are-trading-higher-by-around-56-here-are-20-stocks-moving-premarket

Shares of Beyond Meat, Inc. (NASDAQ: BYND) rose sharply in today’s pre-market trading as the company reported stronger-than-e...

 3d-systems-posts-downbeat-q4-results-joins-eventbrite-lemonade-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 100 points on Wednesday.

 needham-maintains-buy-on-recursion-pharmaceuticals-raises-price-target-to-17

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and raises the price target from $15 t...

 whats-going-on-with-recursion-pharmaceuticals-stock-tuesday

Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinica...

 recursion-pharmaceuticals-q4-2023-gaap-eps-042-beats-044-estimate-sales-1089m-miss-2035m-estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION